290 articles in this topic
A landmark 500-patient RCT finds sodium bicarbonate offers no benefit over placebo for critically ill adults with metabolic acidosis and shock.
A newly identified protein shields the liver from alcohol injury by bridging mitochondria and fat droplets to enhance fatty acid oxidation.
A systematic review of 10 longitudinal studies finds elevated pancreatic fat strongly predicts future type 2 diabetes and glycemic decline.
Machine learning clusters CGM data into four distinct glycemic patterns, each linked to unique diabetic complication risks.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
A global study of 7,040 cirrhosis inpatients finds CKD present in 18% of cases, dramatically worsening outcomes including AKI and mortality.
UCLA researchers outline best practices for respirometry, the gold-standard method for measuring cellular energy and mitochondrial function.
A real-world study of 15,000+ patients finds tirzepatide outperforms both semaglutide and liraglutide in preventing major cardiac events.
Updated review of anti-obesity medications in MASLD finds GLP-1 agonists reduce steatosis and fibrosis, while newer dual/triple agonists show even greater metabolic promise.
A systematic review of 38 trials finds tirzepatide cuts HbA1c nearly 3x more than lixisenatide with similar GI side effect rates.
A Bayesian network meta-analysis of 19 RCTs finds retatrutide tops weight loss but dual agonists offer the best efficacy-safety balance.
New review reveals GLP-1 receptor agonists may cause significant muscle mass loss, raising sarcopenia concerns for millions of users.
